Literature DB >> 20104211

Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice.

Julie Dumonceaux1, Solenne Marie, Cyriaque Beley, Capucine Trollet, Alban Vignaud, Arnaud Ferry, Gillian Butler-Browne, Luis Garcia.   

Abstract

Duchenne muscular dystrophy is characterized by muscular atrophy, fibrosis, and fat accumulation. Several groups have demonstrated that in the mdx mouse, the exon-skipping strategy can restore a quasi-dystrophin in almost 100% of the muscle fibers. On the other hand, inhibition of the myostatin pathway in adult mice has been described to enhance muscle growth and improve muscle force. Our aim was to combine these two strategies to evaluate a possible additive effect. We have chosen to inhibit the myostatin pathway using the technique of RNA interference directed against the myostatin receptor AcvRIIb mRNA (sh-AcvRIIb). The restoration of a quasi-dystrophin was mediated by the vectorized U7 exon-skipping technique (U7-DYS). Adeno-associated vectors carrying either the sh-AcvrIIb construct alone, the U7-DYS construct alone, or a combination of both constructs were injected in the tibialis anterior (TA) muscle of dystrophic mdx mice. We show that even if each separate approach has some effects on muscle physiology, the combination of the dystrophin rescue and the downregulation of the myostatin receptor is required to massively improve both the tetanic force and the specific force. This study provides a novel pharmacogenetic strategy for treatment of certain neuromuscular diseases associated with muscle wasting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20104211      PMCID: PMC2890116          DOI: 10.1038/mt.2009.322

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.

Authors:  Susan Fletcher; Kaite Honeyman; Abbie M Fall; Penny L Harding; Russell D Johnsen; Steve D Wilton
Journal:  J Gene Med       Date:  2006-02       Impact factor: 4.565

2.  Regulation of muscle growth by multiple ligands signaling through activin type II receptors.

Authors:  Se-Jin Lee; Lori A Reed; Monique V Davies; Stefan Girgenrath; Mary E P Goad; Kathy N Tomkinson; Jill F Wright; Christopher Barker; Gregory Ehrmantraut; James Holmstrom; Betty Trowell; Barry Gertz; Man-Shiow Jiang; Suzanne M Sebald; Martin Matzuk; En Li; Li-Fang Liang; Edwin Quattlebaum; Ronald L Stotish; Neil M Wolfman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

3.  Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle.

Authors:  R Kambadur; M Sharma; T P Smith; J J Bass
Journal:  Genome Res       Date:  1997-09       Impact factor: 9.043

4.  Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle.

Authors:  L Grobet; D Poncelet; L J Royo; B Brouwers; D Pirottin; C Michaux; F Ménissier; M Zanotti; S Dunner; M Georges
Journal:  Mamm Genome       Date:  1998-03       Impact factor: 2.957

5.  Myostatin propeptide-mediated amelioration of dystrophic pathophysiology.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Lisa-Anne Whittemore; Tejvir S Khurana
Journal:  FASEB J       Date:  2005-04       Impact factor: 5.191

6.  Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.

Authors:  Simone Abmayr; Paul Gregorevic; James M Allen; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2005-09       Impact factor: 11.454

7.  Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.

Authors:  Qi Long Lu; Adam Rabinowitz; Yun Chao Chen; Toshifumi Yokota; HaiFang Yin; Julia Alter; Atif Jadoon; George Bou-Gharios; Terence Partridge
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

8.  Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.

Authors:  Aurélie Goyenvalle; Adeline Vulin; Françoise Fougerousse; France Leturcq; Jean-Claude Kaplan; Luis Garcia; Olivier Danos
Journal:  Science       Date:  2004-11-04       Impact factor: 47.728

9.  Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino.

Authors:  B Wu; P Lu; E Benrashid; S Malik; J Ashar; T J Doran; Q L Lu
Journal:  Gene Ther       Date:  2009-09-17       Impact factor: 5.250

Review 10.  RNA interference: from gene silencing to gene-specific therapeutics.

Authors:  Ray K M Leung; Paul A Whittaker
Journal:  Pharmacol Ther       Date:  2005-08       Impact factor: 12.310

View more
  32 in total

1.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.

Authors:  Jia Li; Maureen Fredericks; Marishka Cannell; Kathryn Wang; Dianne Sako; Michelle C Maguire; Rosa Grenha; Katia Liharska; Lavanya Krishnan; Troy Bloom; Elitza P Belcheva; Pedro A Martinez; Roselyne Castonguay; Sarah Keates; Mark J Alexander; Hyunwoo Choi; Asya V Grinberg; R Scott Pearsall; Paul Oh; Ravindra Kumar; Rajasekhar Nvs Suragani
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

3.  Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.

Authors:  Louise R Rodino-Klapac; Paul M L Janssen; Kimberly M Shontz; Benjamin Canan; Chrystal L Montgomery; Danielle Griffin; Kristin Heller; Leah Schmelzer; Chalonda Handy; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Hum Mol Genet       Date:  2013-07-17       Impact factor: 6.150

4.  AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.

Authors:  Maëva Le Hir; Aurélie Goyenvalle; Cécile Peccate; Guillaume Précigout; Kay E Davies; Thomas Voit; Luis Garcia; Stéphanie Lorain
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

5.  Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.

Authors:  Ngoc B Lu-Nguyen; Susan A Jarmin; Amer F Saleh; Linda Popplewell; Michael J Gait; George Dickson
Journal:  Mol Ther       Date:  2015-05-11       Impact factor: 11.454

6.  Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.

Authors:  Dwi U Kemaladewi; Willem M H Hoogaars; Sandra H van Heiningen; Samuel Terlouw; David J J de Gorter; Johan T den Dunnen; Gert Jan B van Ommen; Annemieke Aartsma-Rus; Peter ten Dijke; Peter A C 't Hoen
Journal:  BMC Med Genomics       Date:  2011-04-20       Impact factor: 3.063

7.  Impaired adaptive response to mechanical overloading in dystrophic skeletal muscle.

Authors:  Pierre Joanne; Christophe Hourdé; Julien Ochala; Yvain Caudéran; Fadia Medja; Alban Vignaud; Etienne Mouisel; Wahiba Hadj-Said; Ludovic Arandel; Luis Garcia; Aurélie Goyenvalle; Rémi Mounier; Daria Zibroba; Kei Sakamoto; Kei Sakamato; Gillian Butler-Browne; Onnik Agbulut; Arnaud Ferry
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

8.  Impaired skeletal muscle regeneration in the absence of fibrosis during hibernation in 13-lined ground squirrels.

Authors:  Eva Andres-Mateos; Rebeca Mejias; Arshia Soleimani; Brian M Lin; Tyesha N Burks; Ruth Marx; Benjamin Lin; Richard C Zellars; Yonggang Zhang; David L Huso; Tom G Marr; Leslie A Leinwand; Dana K Merriman; Ronald D Cohn
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

9.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10

10.  Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.

Authors:  Alberto Malerba; Jagjeet K Kang; Graham McClorey; Amer F Saleh; Linda Popplewell; Michael J Gait; Matthew Ja Wood; George Dickson
Journal:  Mol Ther Nucleic Acids       Date:  2012-12-18       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.